Alaunos Therapeutics, Inc.

Informe acción NasdaqCM:TCRT

Capitalización de mercado: US$3.8m

Alaunos Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Alaunos Therapeutics es Dale Hogue, nombrado en Jan 2024, tiene una permanencia de menos de un año. posee directamente un 0.25% de las acciones de la empresa, con un valor de $9.56K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 3.9 años, respectivamente.

Información clave

Dale Hogue

Chief Executive Officer (CEO)

US$11.1k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEOless than a year
Participación del CEO0.2%
Permanencia media de la dirección3yrs
Promedio de permanencia en la Junta Directiva3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

CEO

Dale Hogue (54 yo)

less than a year

Permanencia

US$11,090

Compensación

Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.6k
Melinda Lackey
Senior VP of Legal3yrsUS$701.74ksin datos
Michael Wong
Vice President of Finance & Principal Accounting Officer3.2yrssin datossin datos

3.0yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TCRT se considera experimentado (3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.6k
Holger Weis
Independent Chairman of the Board3.9yrsUS$900.26k0.076%
$ 2.9k
Carl June
Chairman of Scientific Advisory Board4.4yrssin datossin datos
Jaime Vieser
Independent Director3.9yrsUS$103.26k0.97%
$ 37.0k
Matthew Porteus
Member of Scientific Advisory Board4.2yrssin datossin datos
Kole Roybal
Member of Scientific Advisory Board4.2yrssin datossin datos
Robert Hofmeister
Independent Director1.7yrsUS$84.01k0%
$ 0
Robert Postma
Independent Director3.8yrsUS$104.26k0.52%
$ 19.8k
Steven Feldman
Member of Scientific Advisory Boardno datasin datossin datos

3.9yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de TCRT se considera experimentada (3.9 años de antigüedad promedio).